{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T21:31:51Z","timestamp":1772055111975,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.ejphar.2003.12.014","type":"journal-article","created":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T10:19:43Z","timestamp":1074766783000},"page":"189-200","source":"Crossref","is-referenced-by-count":41,"title":["In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome"],"prefix":"10.1016","volume":"486","author":[{"given":"Katsuyoshi","family":"Chiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Takasuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2003.12.014_BIB1","first-page":"806","article-title":"Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics","volume":"296","author":"Anderson","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-200140030-00003","article-title":"Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials","volume":"40","author":"Aminimanizani","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"Topic T1","key":"10.1016\/j.ejphar.2003.12.014_BIB3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone generations: natural history or natural selection?","volume":"46","author":"Ball","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB4","first-page":"353","article-title":"An analysis of the time-relations of electrocardiogram","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0149-2918(00)80053-3","article-title":"The safety profile of the fluoroquinolones","volume":"22","author":"Bertino","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1086\/339075","article-title":"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors","volume":"34","author":"Bertino","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0014-2999(00)00693-2","article-title":"Effects of fluoroquinolones on HERG currents","volume":"406","author":"Bischoff","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199008000-00014","article-title":"QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions","volume":"16","author":"Carlsson","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB9","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/cvr\/27.12.2186","article-title":"Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations","volume":"27","author":"Carlsson","year":"1993","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/taap.2000.9041","article-title":"Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades","volume":"169","author":"Chiba","year":"2000","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1365-2125.1996.03394.x","article-title":"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers","volume":"41","author":"Demolis","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","article-title":"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects","volume":"68","author":"D\u00e9molis","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002280100290","article-title":"Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus","volume":"57","author":"De Ponti","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF01695673","article-title":"Torsades de pointe probably related to sparfloxacin","volume":"15","author":"Dupont","year":"1996","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1540-8167.1994.tb01192.x","article-title":"Bridging the gap between basic and clinical electrophysiology: what can be learned from monophasic action potential recordings?","volume":"5","author":"Franz","year":"1994","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.77.5.1177","article-title":"Frequency-dependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ","volume":"77","author":"Franz","year":"1988","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2003.12.014_BIB17","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/314061","article-title":"Clinical pharmacology of gatifloxacin, a new fluoroquinolone","volume":"31","author":"Grasela","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00005344-200105000-00012","article-title":"The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis","volume":"37","author":"Gintant","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1254\/jjp.87.231","article-title":"A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia","volume":"87","author":"Hagiwara","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0008-6363(00)00119-X","article-title":"The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications report on a policy conference of the European society of cardiology","volume":"47","author":"Haverkamp","year":"2000","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2003.12.014_BIB21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1592\/phco.21.3.361.34204","article-title":"Gatifloxacin-induced QTc prolongation and ventricular tachycardia","volume":"21","author":"Iannini","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB23","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.CIR.97.25.2567","article-title":"Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects","volume":"97","author":"Kirchhof","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB24","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1128\/AAC.44.10.2600-2603.2000","article-title":"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers","volume":"44","author":"Lubasch","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","article-title":"Effects of three fluoroquinolones on QT interval in healthy adults after single doses","volume":"73","author":"Noel","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/0049825011","article-title":"Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects","volume":"31","author":"O'Grady","year":"2001","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.ejphar.2003.12.014_BIB27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1592\/phco.21.3.301.34206","article-title":"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes","volume":"21","author":"Owens","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0014-2999(00)00694-4","article-title":"Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration","volume":"406","author":"Patmore","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/01.CIR.94.2.217","article-title":"Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs","volume":"94","author":"Satoh","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00005344-200010000-00015","article-title":"QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring","volume":"36","author":"Satoh","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bmj.322.7277.23","article-title":"Tachycardia associated with moxifloxacin","volume":"322","author":"Siepmann","year":"2001","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-4347(97)00371-X","article-title":"Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing","volume":"702","author":"Stass","year":"1997","journal-title":"J. Chromatogr., B, Biomed. Sci. Appl."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/taap.1998.8494","article-title":"Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring","volume":"152","author":"Sugiyama","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1254\/jjp.88.414","article-title":"Effects of a typical IKr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes","volume":"88","author":"Sugiyama","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/taap.2001.9168","article-title":"In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol","volume":"173","author":"Sugiyama","year":"2001","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1254\/jjp.88.341","article-title":"Electrophysical, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs","volume":"88","author":"Sugiyama","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00005344-200208000-00009","article-title":"Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models","volume":"40","author":"Sugiyama","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(03)01559-0","article-title":"Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems","volume":"466","author":"Sugiyama","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jjp.83.1","article-title":"Drug-induced torsade de pointes: from molecular biology to bedside","volume":"83","author":"Tamargo","year":"2000","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB40","unstructured":"The ICH Steering Committee, 2002. Draft Consensus Guideline, Safety Pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Guideline was released for consultation under Step 2 of the ICH Process in February 2002 http:\/\/www.ich.org\/)."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/01.CIR.98.11.1136","article-title":"Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes","volume":"98","author":"Volders","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB42","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1161\/01.CIR.100.24.2455","article-title":"Downregulation of delayed rectifier K+ currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes","volume":"100","author":"Volders","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2003.12.014_BIB43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/43.suppl_2.91","article-title":"Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone","volume":"43","author":"Von Keutz","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2003.12.014_BIB44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.CIR.98.11.1125","article-title":"Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling","volume":"98","author":"Vos","year":"1998","journal-title":"Circulation"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299903027821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299903027821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T12:54:01Z","timestamp":1550235241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299903027821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0014299903027821"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2003.12.014","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}